Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer

BACKGROUND: Treatment options for metastatic breast cancer (MBC) refractory to anthracyclines and taxanes are limited. In a phase III trial, eribulin demonstrated a significant improvement in overall survival compared to treatment of physician’s choice, but had limited tolerability because of neutro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalasani, Pavani, Farr, Kiah, Wu, Vicky, Jenkins, Isaac, Liu, Alex, Parker, Stephanie, Gadi, Vijayakrishna K., Specht, Jennifer, Linden, Hannah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233258/
https://www.ncbi.nlm.nih.gov/pubmed/33797651
http://dx.doi.org/10.1007/s10549-021-06175-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233258/
https://www.ncbi.nlm.nih.gov/pubmed/33797651
http://dx.doi.org/10.1007/s10549-021-06175-x

Ejemplares similares